

Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®

May 28, 2018

- - Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)¹
- - These improvements were reported early by Entresto patients, with a median follow-up time of 32 days¹
- - 21.4 percent of patients treated with Entresto in this interim data cut reported a large improvement (>20-point difference from baseline) in the overall summary score versus 12.5 percent of patients not taking Entresto¹

EAST HANOVER, N.J., May 28, 2018 /PRNewswire/ -- Novartis announced today new real world evidence from the CHAMP-HF registry comparing Entresto® (sacubitril/valsartan) patients to patients not taking Entresto.¹ This pre-specified analysis of an interim data cut from the CHAMP-HF registry showed that chronic heart failure (HF) patients with reduced ejection fraction (HFrEF) taking Entresto reported early, statistically significant improvement in health status, as measured by the KCCQ-12 overall summary score (KCCQ-OS).¹ This finding was driven by statistically significant improvements in symptom frequency and quality of life domains of the KCCQ-12.¹ The study findings were presented today by lead investigator Yevgeniy Khariton, MD, MSc, Saint Luke's Hospital, Mid-America Heart Institute, University of Missouri-Kansas City, as a part of a late-breaking session at the European Society of Cardiology Heart Failure (ESC-HF) Congress in Vienna, Austria.

"Key goals in managing chronic heart failure are to improve patients' symptoms and quality of life," said CHAMP-HF Chair Gregg C. Fonarow, MD and Director of the Ahmanson-UCLA Cardiomyopathy Center, Co-Chief of UCLA's Division of Cardiology, and Co-director of UCLA's Preventative Cardiology Program. "These findings in a real world setting are important because they suggest that taking sacubitril/valsartan may help patients achieve these goals."

"In addition to the already reported reduction in risk of cardiovascular death and heart failure hospitalization in HFrEF patients treated with Entresto, we now show its potential to improve patient-reported health status," said Shreeram Aradhye, MD, Chief Medical Officer and Global Head, Medical Affairs, Novartis Pharmaceuticals.^{1,2} "What we find most encouraging is that both our Entresto clinical program and now this real world analysis have shown health status benefits as measured by KCCQ."

About KCCQ-12

KCCQ-12 is a self-administered, health status tool for patients with heart failure.³ There are four domains: physical limitation (showing/bathing, walking one block on level ground, hurrying or jogging), symptom frequency (shortness of breath, fatigue and swelling of the feet, ankles and legs), social limitation (hobbies/recreational activities, working/doing household chores, visiting family/friends out of the home) and quality of life (impact on lifestyle and satisfaction of spending rest of life with current HF status).³ Each domain is scored separately, and the overall summary score is equal to the mean of the four domain scores.³ Higher

KCCQ-12 scores from baseline represent better health status.³ An intra-individual change in a patient's score of 3 to 5 points, or a ≥ 5 point mean group difference, is defined as a minimal clinically important difference for the KCCQ-12 summary score.³

About the CHAMP-HF Registry

CHAnge the Management of Patients with Heart Failure (CHAMP-HF) is an ongoing, prospective, observational outpatient disease registry in patients with chronic HFrEF (left ventricular ejection fraction $\leq 40\%$).⁴ CHAMP-HF has enrolled approximately 5,000 patients from 150 geographically diverse US sites, following these patients, including those who have been hospitalized, for a maximum duration of 24 months.⁴ Participating sites are collecting data from providers (HF history, examination findings, and results of diagnostic studies, pharmacotherapy treatment patterns, decision-making factors, and clinical outcomes) and patients (medication adherence and patient-reported outcomes such as KCCQ-12).⁴ The primary endpoint of CHAMP-HF is to examine the rationale for HF treatment changes.⁴ Secondary outcomes include examining patient and provider decisions and perceptions of treatments, as well as HF related health care resource utilization.⁴ Quality of life measures, such as KCCQ-12 and European Quality of Life Five Dimensions (EQ-5D) Questionnaire, and depression screening (PHQ-2), are also being examined as exploratory outcomes.⁴ This real world contemporary registry provides a unique opportunity to study practice patterns, patient-reported outcomes and the adoption of new HF therapies across a diverse mix of health care providers and practices in the US that care for HFrEF patients.⁴

About the Real World Evidence Analysis

Presented today was a pre-specified analysis of an interim data cut from CHAMP-HF.¹ The aim of this analysis was to assess short-term, health status benefits of Entresto in real world US clinical practice.¹ Propensity score matching was conducted using 365 Entresto patients and 730 patients not receiving Entresto (1:2 match).¹

Patients taking Entresto had statistically significant improvement in health status as measured by the mean group difference in KCCQ overall summary score (KCCQ-OS) compared to those not taking Entresto (6.01 ± 19 vs. 3.55 ± 17 , $p=0.014$).¹ This improvement in the KCCQ score was seen early with a median follow up of 32 days reported (interquartile range 26, 53).¹ Patients on Entresto scored numerically higher on all domains compared to patients not taking Entresto, but the improvement in the KCCQ-OS score was driven by statistically significant improvements in two domains: symptom frequency (5.07 vs. 1.60, $p=0.007$) and quality of life (7.53 vs. 4.09, $p=0.021$).¹ The proportion of patients with a large improvement in overall score (defined as a greater than 20-point improvement from baseline) was 21.4% (78 out of 365 patients) for those taking Entresto vs. 12.5% (91 out of 730 patients) for those not taking Entresto, suggesting a number needed to treat (NNT) of 11.¹

The overall findings of this real world matched analysis are in line with the KCCQ findings in the PARADIGM-HF study, which showed that Entresto had a positive impact on the health status of patients with chronic heart failure.^{5,6}

Methods

Study Design¹

- This is a comparative real world effectiveness analysis in which Entresto and non-Entresto groups were propensity matched based on 6 sociodemographic characteristics, 25 clinical characteristics and most recent KCCQ

- Study sample: Patients in the CHAMP-HF registry, who were not previously taking Entresto prior to enrollment, had ≥ 1 KCCQ assessment before their Entresto start and no contraindications to Entresto
- Cohort definition:
 - Entresto use: New Entresto starts (any report of use after enrollment)
 - No Entresto use: Patients with no report of any use of Entresto after enrollment
- Outcome evaluated:
 - KCCQ-12 overall summary scores (primary) and 4 domain scores (secondary) at first assessment after Entresto initiation

It is important to note that the nature of this real world evidence has some limitations:

- 50% of patients in the comparison arm did not receive an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) during matching, which may impact the findings
- Observational analyses have the potential for residual confounding and can only test for associations as opposed to causality (tested via randomized clinical trials)
- It was not possible to exclude patient bias resulting from open-label Entresto use, which could cause a placebo effect on the Entresto arm

About Heart Failure

Heart failure (HF) is a chronic and progressive condition, which impacts 6.5 million Americans and is the leading cause of hospitalization among Americans over the age of 65.^{7,8} About half of people with HF have heart failure with reduced ejection fraction (HFrEF), also known as systolic HF.^{9,10} Reduced ejection fraction means the heart does not contract with enough force, so less blood is pumped out.¹¹ HF presents a major and growing health-economic burden that currently exceeds \$30 billion in the United States, which accounts for both direct and indirect costs.¹²

Novartis has established the largest global clinical program in the HF disease area across the pharma industry to date. Known as FortiHFy, it is comprised of more than 40 active or planned clinical studies designed to generate an array of additional data on symptom reduction, efficacy, quality of life benefits and real world evidence with Entresto, as well as to extend understanding of heart failure.

About Entresto

Entresto is a prescription medicine used to reduce the risk of death and hospitalization in people with certain types of long-lasting (chronic) heart failure.² Entresto is usually used with other heart failure therapies, in place of an ACE inhibitor or other ARB therapy.² Entresto is a twice-a-day prescription medicine that reduces the strain on the failing heart.² It does this by enhancing the protective neurohormonal systems (natriuretic peptide system) while simultaneously inhibiting the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS).^{2,13} Other heart failure medicines only block the harmful effects of the overactive RAAS.¹⁰ Entresto contains the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan.² Entresto film-coated tablets are available in three dosage strengths: 24/26 mg, 49/51 mg, and 97/103 mg (sacubitril/valsartan).² These doses are referred to as 50 mg, 100 mg, and 200 mg in the clinical trial literature including The New England Journal of Medicine publication of the results of PARADIGM-HF. The target maintenance dose of Entresto is 97/103 mg twice daily.²

IMPORTANT SAFETY INFORMATION

Entresto can harm or cause death to an unborn baby. Patients should talk to their doctor about other ways to treat heart failure if they plan to become pregnant. If a patient gets pregnant while taking Entresto, she should tell her doctor right away.

Patients are not to take Entresto if they are allergic to sacubitril or valsartan or any of the ingredients in Entresto; have had an allergic reaction including swelling of the face, lips, tongue, throat or trouble breathing while taking a type of medicine called angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB); or take an ACE inhibitor medicine. Patients are not to take Entresto for at least 36 hours before or after they take an ACE inhibitor medicine. Patients should talk with their doctor or pharmacist before taking Entresto if they are not sure if they take an ACE inhibitor medicine. Patients are not to take Entresto if they have diabetes and take a medicine that contains aliskiren.

Before they take Entresto, patients should tell their doctor about all of their medical conditions, including if they have kidney or liver problems; or a history of hereditary angioedema; are pregnant or plan to become pregnant; are breastfeeding or plan to breastfeed. Patients should either take Entresto or breastfeed. They should not do both.

Patients should tell their doctor about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. They should especially tell their doctor if they take potassium supplements or a salt substitute; nonsteroidal anti-inflammatory drugs (NSAIDs); lithium; or other medicines for high blood pressure or heart problems such as an ACE inhibitor, ARB, or aliskiren.

Entresto may cause serious side effects including serious allergic reactions causing swelling of the face, lips, tongue, and throat (angioedema) that may cause trouble breathing and death. Patients are to get emergency medical help right away if they have symptoms of angioedema or trouble breathing. Patients are not to take Entresto again if they have had angioedema while taking Entresto. People who are black or who have had angioedema may have a higher risk of having angioedema if they take Entresto. Entresto may cause low blood pressure (hypotension). Patients are to call their doctor if they become dizzy or lightheaded, or they develop extreme fatigue. Entresto may cause kidney problems or an increased amount of potassium in the blood.

The most common side effects were low blood pressure, high potassium, cough, dizziness, and kidney problems.

Please see full Prescribing Information, including Boxed WARNING available at <http://www.pharma.us.novartis.com/product/pi/pdf/entresto.pdf>.

Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Novartis is committed to providing patients with affordable access and resources through Entresto Central. For more information, please call 1-888-ENTRESTO or visit www.entresto.com.

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for

sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 124,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit <http://www.novartis.com>.

Novartis is on Twitter. Sign up to follow @Novartis at <http://twitter.com/novartis>

For Novartis multimedia content, please visit www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

References

1. Khariton, Y, Fonarow, GC, et al. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure with Reduced Ejection Fraction: Findings from the CHAMP-HF Registry. Data presented at the European Society of Cardiology Heart Failure (ESC-HF); 2018 May 26-29; Vienna, Austria.
2. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; November 2017.
3. Spertus, JA, Jones, PG. Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. *Circulation: Cardiovascular Quality and Outcomes*. 2015;8:469-476. DOI: 10.1161/CIRCOUTCOMES.115.001958.
4. DeVore, AD, Thomas, L, et al. Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. *Am Heart J* 2017;189:177-183.
5. Chandra, A, Lewis AF, et al. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients with Heart Failure A Secondary Analysis of the PARADIGM-HF Trial. *JAMA Cardiology*. 2018;3(5):1-8. doi:10.1001/jamacardio.2018.0398. 2014;371(11):993-1004.
6. Lewis, EF, Claggett, BL, et al. Health-Related Quality of Life Outcomes in PARADIGM-HF. *Circulation: Heart Failure*. 2017;10:e003430. DOI: <https://doi.org/10.1161/CIRCHEARTFAILURE.116.003430>.
7. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. *Circulation*. 2018;137(12):e67-e492.

8. Weir LM, Pfuntner A, Maeda J, et al. HCUP Facts and Figures: Statistics on Hospital-based Care in the United States, 2009. Agency for Healthcare Research and Quality. 2011;1-3.
9. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.
10. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;128:e240-e327.
11. Ejection Fraction Heart Failure Measurement. American Heart Association Website. http://www.heart.org/HEARTORG/Conditions/HeartFailure/SymptomsDiagnosisofHeartFailure/Ejection-Fraction-Heart-Failure-Measurement_UCM_306339_Article.jsp (link is external). Published March 24, 2015. Accessed April 13, 2018.
12. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606-619.
13. Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today. 2012;4: e131-139.

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Eric Althoff	Phil McNamara
Novartis Global Media Relations	Novartis US Pharma Communications
+41 61 324 7999 (direct)	+1 862 778 0218 (direct)
+41 79 593 4202 (mobile)	+1 862 274 5255 (mobile)
eric.althoff@novartis.com	philip.mcnamara@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central

North America

Samir Shah

+41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

SOURCE Novartis

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/patient-reported-outcomes-tool-revealed-significant-improvement-symptom-frequency-and-quality-life-domains-entresto>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/patient-reported-outcomes-tool-revealed-significant-improvement-symptom-frequency-and-quality-life-domains-entresto>
2. <http://www.pharma.us.novartis.com/product/pi/pdf/entresto.pdf>
3. <http://www.fda.gov/medwatch>
4. <http://www.entresto.com/>
5. <http://www.novartis.com/>
6. <http://twitter.com/novartis>
7. <http://www.novartis.com/news/media-library>
8. <mailto:media.relations@novartis.com>
9. <https://doi.org/10.1161/CIRCHEARTFAILURE.116.003430>
10. http://www.heart.org/HEARTORG/Conditions/HeartFailure/SymptomsDiagnosisofHeartFailure/Ejection-Fraction-Heart-Failure-Measurement_UCM_306339_Article.jsp
11. <mailto:media.relations@novartis.com>
12. <mailto:eric.althoff@novartis.com>
13. <mailto:philip.mcnamara@novartis.com>
14. <mailto:investor.relations@novartis.com>